CIPLA Share Price, Analysis & News

Cipla (CIPLA) — Updated on 2026-06-22

Cipla Limited is an India-based global pharmaceutical company operating within the biotechnology & drugs industry. The company is involved in the manufacturing, development, and marketing of a diverse array of branded and generic formulations, alongside Active Pharmaceutical Ingredients (APIs). Investors closely monitor Cipla share price to understand its market performance and growth trajectory. Analyzing the Cipla business model provides insights into its operational strategies and revenue streams. The company's performance is often viewed in the context of broader trends in the pharmaceutical sector, including regulatory changes and advancements in drug development, which can impact its fundamental financial health and earnings.

Key Takeaway

Cipla's stock shows recent strength driven by Citi's positive catalyst watch for US approvals, overshadowing recent fundamental declines.

Daily

2026-06-22
  • Cipla's stock experienced a positive surge, driven by Citi's 'Buy' rating and inclusion in a 90-day Positive Catalyst Watch, signaling potential upside from upcoming US approvals like generic Flovent and Ventolin.
  • Technically, the stock shows a bullish trend with its price above key Exponential Moving Averages (EMAs) and a bullish crossover, indicating positive short-term momentum with an RSI of 60.98.
  • Despite recent positive price action, the company's fundamental performance shows a downward trend, with revenue, net profit, and EPS declining both quarter-over-quarter and year-over-year.
  • Institutional investors maintain a significant stake, with a notable shift this quarter showing Foreign Institutional Investors (FIIs) decreasing their holdings by 1.38% while Domestic Institutional Investors (DIIs) increased theirs by 1.26%.
  • Recent company announcements include a newspaper publication regarding share transfers to the Investor Education and Protection Fund and the appointment of Shivam Puri as CEO of its One India Business, effective July 1, 2026.
Open daily analysis

Weekly

Latest weekly signal
  • The stock declined 2.72% this week, driven by weakening technical momentum and a mixed fundamental outlook.
  • Trading volume surged by 43.09% WoW, indicating increased investor interest despite the price decline.
  • The appointment of Shivam Puri as CEO of One India Business was announced, effective July 1.
  • USFDA classified the Verna, Goa facility inspection as Voluntary Action Indicated (VAI), suggesting no significant issues.
  • The stock is trading below its 50-day and 200-day moving averages, with weakening momentum indicated by a falling RSI and negative MACD.
Open weekly analysis

Quarterly

fy26-q4
  • Net Profit declined significantly to ₹543 Crores, down 55% year-over-year and 20% quarter-over-quarter, indicating a substantial drop in profitability. Revenue from operations also decreased, falling 3% year-over-year to ₹6,541 Crores and 8% quarter-over-quarter, reflecting a contraction in sales. Total Expenses increased 8% year-over-year to ₹5,982 Crores, contributing to the decline in net profit despite a quarter-over-quarter decrease. Non-current borrowings rose sharply year-over-year from ₹12.0 Crores to ₹117 Crores, indicating increased long-term debt. Cash and cash equivalents saw a strong increase of 73% year-over-year, reaching ₹1,018 Crores, providing improved liquidity.
Open quarterly analysis

Price & Technical Structure

  • The stock has shown positive short-term returns, with a 4.73% gain in the last day and 10.45% over the last three months.
  • A bullish trend is indicated by the price being above the 9, 21, and 50-day EMAs, with a bullish crossover observed.
  • Momentum is neutral to positive, with an RSI of 60.98 and an RSI percentile of 84.98 over the past year.
  • The stock is trading within the Bollinger Bands, near the upper band, suggesting increased volatility.
  • The stock is trading 14.82% below its 52-week high and 18.84% above its 52-week low, with a current drawdown of -14.82%.
The stock exhibits a bullish technical setup, characterized by positive short-term returns and a strong uptrend indicated by EMA crossovers and alignment. Momentum is in a neutral to positive zone. While the stock is trading near its 52-week high, it remains within the Bollinger Bands, suggesting some volatility. The current drawdown is within historical limits.

Weekly Momentum

  • The stock declined 2.72% this week, driven by weakening technical momentum and a mixed fundamental outlook.
  • Trading volume surged by 43.09% WoW, indicating increased investor interest despite the price decline.
  • The appointment of Shivam Puri as CEO of One India Business was announced, effective July 1.
  • USFDA classified the Verna, Goa facility inspection as Voluntary Action Indicated (VAI), suggesting no significant issues.
  • The stock is trading below its 50-day and 200-day moving averages, with weakening momentum indicated by a falling RSI and negative MACD.
Cipla experienced a notable price decline this week, accompanied by a significant surge in trading volume. Technical indicators suggest weakening momentum, with the stock trading below key moving averages. Recent corporate events, including a leadership change and a positive USFDA inspection outcome, provide some context, but the overall technical picture points to caution. The company's recent quarterly results showed a year-over-year decrease in revenue and net profit, contributing to the mixed sentiment.

Quarterly Analysis

Net Profit declined significantly to ₹543 Crores, down 55% year-over-year and 20% quarter-over-quarter, indicating a substantial drop in profitability.
Revenue from operations also decreased, falling 3% year-over-year to ₹6,541 Crores and 8% quarter-over-quarter, reflecting a contraction in sales.
Total Expenses increased 8% year-over-year to ₹5,982 Crores, contributing to the decline in net profit despite a quarter-over-quarter decrease.
Non-current borrowings rose sharply year-over-year from ₹12.0 Crores to ₹117 Crores, indicating increased long-term debt.
Cash and cash equivalents saw a strong increase of 73% year-over-year, reaching ₹1,018 Crores, providing improved liquidity.
The quarter's performance was dominated by a significant decline in both revenue and net profit, driven by increased expenses year-over-year. While cash reserves improved, the substantial rise in non-current borrowings indicates a shift in the company's financial leverage.
The company experienced a significant downturn in its financial performance this quarter, with both revenue and net profit declining substantially. Revenue from operations was ₹6,541 Crores, a decrease of 3% year-over-year and 8% quarter-over-quarter. This contraction in sales signals a weakening in the company's top line.

Profitability was heavily impacted, with Net Profit declining to ₹543 Crores. This represents a 55% decrease year-over-year and a 20% decrease quarter-over-quarter. The decline in net profit was exacerbated by an 8% year-over-year increase in Total Expenses to ₹5,982 Crores, even though expenses decreased by 2% quarter-over-quarter. Employee Benefit Expense, a key component of operating costs, rose 15% year-over-year.

The company's balance sheet reflects a notable shift in its financing structure. Non-current borrowings increased significantly year-over-year, from ₹12.0 Crores to ₹117 Crores. This indicates a greater reliance on long-term debt financing. In contrast, Cash and Cash Equivalents saw a substantial improvement, growing by 73% year-over-year to ₹1,018 Crores, which suggests enhanced liquidity.